Wei Zhang

Wei Zhang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
CWCongxiao Wang
Congxiao Wang
CTChuan Tian
Chuan Tian
DCDuo Cai
Duo Cai
HJHan Jiang
Han Jiang
WZWei Zhang
Wei Zhang
XHXiaokun Hu
Xiaokun Hu
Background: Ischemic stroke treatment is a challenge worldwide. The efficacy and safety of mesenchymal stem cells (MSCs) for stroke have been confirmed. However, poor survival of MSCs in the ischemic environment limits the therapy efficacy. Changes in MSC status in the ischemic environment after transplantation is difficult to monitor. This study aimed to deliver brain-derived neurotrophic factor (BDNF)-overexpressing MSCs by hydrogel (H-B-MSCs) to promote recovery after ischemic stroke. Methods: MSCs were transfected with lentivirus carrying luc2 and BDNF cassette. The properties of hydrogel were tested after synthesis with thiolated gelatin (Gel-SH), thiolated hyaluronic acid (HA-SH), and polyethylene glycol diacrylate (PEGDA). Oxygen-glucose deprivation (OGD) test was carried out to confirm the protective effects of hydrogel in the ischemic environment. Three days after stroke induction, H-B-MSCs, hydrogel carrying MSCs (H-MSCs), or phosphate-buffered saline (PBS) was injected into the brains of mice, respectively. Bioluminescence imaging (BLI) was performed at 3, 7, 14, and 21 days post-cell-transplantation to monitor the dynamic status of MSCs. In the meantime, histology, quantitative polymerase chain reaction (qPCR), enzyme-linked immunosorbent assay (ELISA), western blot, and behavior tests were carried out at different time points. Results: Hydrogel with good biocompatibility was synthesized. Lentivirus transfection significantly increased the expression of BDNF. BDNF-MSCs could be tracked by BLI in vitro. In vitro OGD/reperfusion (OGD/R) test results suggested that MSCs carried by hydrogel could survive longer in an environment with low oxygen and glucose. H-B-MSCs significantly improved functional recovery after ischemic stroke. Furthermore, H-B-MSCs treatment promoted neurogenesis, white matter recovery, and angiogenesis after ischemic stroke. MSC dynamics could be monitored in vivo with BLI. Conclusions: We effectively established a robust MSC delivery system with hydrogel. Prolonged survival of transplanted BDNF-MSCs with a hydrogel delivery system could promote the recovery of ischemic stroke via the continuous release of BDNF.

27 January 2021
Verified
Report
Open access
WZWei Zhang
Wei Zhang
YLYi Liu
Yi Liu
DLDongze Li
Dongze Li
YJYu Jia
Yu Jia
INPLASY202110100 Exercise interventions for treating depression after stroke: A protocol for systematic review and meta-analysis Keywords: Post-stroke depression, exercise. Download PDF – 202110100

3 April 2023
Verified
Other
Open access
JSJianfeng Shen
Jianfeng Shen
YPYang Peng
Yang Peng
LWLeizhen Wei
Leizhen Wei
WZWei Zhang
Wei Zhang
YLYang Lin
Yang Lin
GPGuang Peng
Guang Peng
Supplementary Methods from ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors


11 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
XLXinjuan Lei
Xinjuan Lei
WZWei Zhang
Wei Zhang
The adult heart relies on fatty acid β-oxidation for energy, and cardiomyocyte lipid droplets (CLDs) are central to myocardial lipid homeostasis. CLDs are now recognized to protect cardiomyocytes against lipotoxicity, endoplasmic reticulum (ER) stress, oxidative stress, and nutrient deprivation. Moreover, accumulating evidence suggests that CLDs within the same cardiomyocyte are not uniform but may exhibit heterogeneity in size, subcellular localization, protein composition, and metabolism. Here, we propose a conceptual framework that classifies CLD heterogeneity along three dimensions: morphology, organelle connectivity, and molecular composition. We first define the biological characteristics of CLDs and categorize their heterogeneity. We then discuss the molecular pathways maintaining this heterogeneity, their roles in the healthy heart, and their dysregulation in cardiovascular diseases. Finally, we review preclinical strategies targeting CLD heterogeneity and outline challenges and future directions for clinical translation. This framework integrates current evidence while acknowledging that direct molecular validation awaits future single-droplet omics technologies.